Over the past several decades, the approach to the diagnosis and management of patients
with follicular cell‐derived thyroid cancer has evolved based on improved classification of …

Surgery—with or without postoperative radioiodine—is the standard of care for most patients
with differentiated thyroid carcinoma (DTC). Thyroid hormone replacement therapy is the …

Simple Summary Thyroid-stimulating hormone (TSH) plays a role in the regulation of thyroid
hormones and is an important indicator for assessing thyroid function. Thyroid cancer (TC) is …

Differentiated thyroid cancer (DTC) is the most frequent endocrine malignancy and
represents the most rapidly increasing cancer diagnosis worldwide. In the last 20 years, this …

Background: Long-term management of intermediate-and high-risk differentiated thyroid
cancer (DTC) involves thyrotropin (TSH) suppression with thyroid hormone to prevent …

Background The management of intermediate-risk group of papillary thyroid cancer (PTC) is
still vague, particularly regarding whether or not total thyroidectomy, postoperative …

Background To assess the gaps between the initial management of patients with
differentiated thyroid cancer (DTC) in real clinical practice and the recommendations of the …

Objective Thyroid‐stimulating hormone (TSH) suppression treatment can induce signs and
symptoms of hyperthyroidism and hypothyroidism due to inappropriate treatment or poor …

Background High-risk differentiated thyroid cancer (DTC) needs effective early prediction
tools to improving clinical management and prognosis. This cohort study aimed to …

Background: This study aimed to identify the clinical results after thyrotropin suppression
therapy (TST) cessation and evaluated clinical factors associated with successful TST …